Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;115(3):573-582.
doi: 10.1111/add.14820. Epub 2019 Nov 20.

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study)

Tangui Barré  1   2 , Fabienne Marcellin  1   2 , Vincent Di Beo  1   2 , Jessica Delorme  3 , Teresa Rojas Rojas  1   2 , Philippe Mathurin  4 , Camelia Protopopescu  1   2 , François Bailly  5 , Marion Coste  1   2 , Nicolas Authier  3 , Maria Patrizia Carrieri  1   2 , Benjamin Rolland  6
Affiliations

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study)

Tangui Barré et al. Addiction. 2020 Mar.

Abstract

Background and aims: Although people who inject drugs (PWID) are the core at-risk population in the hepatitis C virus (HCV) epidemic in industrialized countries, few initiate treatment. Alcohol use disorder (AUD), common within this population, has been identified as a barrier to HCV treatment uptake in the general population. We investigated whether the arrival of new and well-tolerated HCV treatments (direct-acting antivirals: DAA) has improved HCV treatment uptake in French PWID compared with former treatments (pegylated interferon-based treatments: Peg-IFN).

Design: Using discrete-time Cox proportional hazards models based on exhaustive care delivery data, we tested for associations between AUD (defined by AUD-related long-term illness status, diagnosis coding during hospitalization and/or AUD pharmacological treatment) and first HCV treatment delivery, after adjusting for gender, age, complementary universal health cover, liver disease severity and type of opioid agonist therapy (OAT) received. Separate analyses were performed for 2012-13 (Peg-IFN era) and 2014-16 (DAA era).

Setting: France.

Participants: All French people chronically HCV-infected who received OAT at least once during 2012-16 and were covered by the national health insurance (n = 24 831).

Measurements: Incidence rate of HCV treatment uptake, hazard ratios associated with AUD and other covariates.

Findings: Incidence rate (IR) of HCV treatment uptake per 100 person-years was 6.56, confidence interval (CI) = 6.30-6.84; and IR = 5.70, 95% CI = 5.51-5.89 for Peg-IFN-based treatment (2012-13) and DAA (2014-16), respectively. After multiple adjustment, people with AUD not receiving related medication had 30 and 14% lower Peg-IFN-based treatment and DAA uptake, respectively, than those without AUD [hazard ratio (HR) = 0.70, 95% CI = 0.62-0.80 and HR = 0.86, 95% CI = 0.78-0.94]. No difference was observed between those treated for AUD and those without AUD.

Conclusions: Despite the benefits of direct-acting antiviral treatment, untreated alcohol use disorder appears to remain a major barrier to hepatitis C virus treatment access for people who inject drugs in France.

Keywords: AUD treatment; Alcohol use disorder; France; direct-acting antivirals; hepatitis C virus treatment; people who inject drugs.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stanaway J. D., Flaxman A. D., Naghavi M., Fitzmaurice C., Vos T., Abubakar I., et al The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet 2016; 388: 1081–1088. - PMC - PubMed
    1. Hallager S., Brehm Christensen P., Ladelund S., Rye Clausen M., Lund Laursen A., Møller A., et al Mortality rates in patients with chronic hepatitis C and cirrhosis compared with the general population: a Danish cohort study. J Infect Dis 2017; 215: 192–201. - PubMed
    1. Degenhardt L., Peacock A., Colledge S., Leung J., Grebely J., Vickerman P., et al Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 2017; 5: e1192–e1207. - PMC - PubMed
    1. European Monitoring Centre for Drugs and Drug Addiction . Hepatitis C among drug users in Europe: epidemiology, treatment and prevention [internet]. 2016. Available at: http://www.emcdda.europa.eu/publications/insights/hepatitis-c-among-drug... (accessed 29 August 2018).
    1. Grebely J., Larney S., Peacock A., Colledge S., Leung J., Hickman M., et al Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019; 114: 150–166. - PMC - PubMed

Publication types